Table 2.
Association between vitronectin expression and clinicopathological characteristics in gastric cancer patients.
| VN expression | |||
| Variables | Low (N = 45) | High (N = 57) | P value |
| Gender (%) | .328 | ||
| Male | 38 (84.4) | 43 (75.4) | |
| Female | 7 (15.6) | 14 (24.6) | |
| Age (mean ± SD, yrs) | 66.2 ± 9.9 | 61.2 ± 11.2 | .021 |
| ASA | .222 | ||
| 1 | 22 (48.9) | 36 (63.2) | |
| 2 | 20 (44.4) | 20 (35.1) | |
| 3 | 3 (6.7) | 1 (1.8) | |
| Operative time, min | 209.4 ± 34.6 | 219.6 ± 54.0 | .272 |
| Estimated blood loss, mL | 322.9 ± 212.2 | 399.5 ± 242.6 | .098 |
| Tumor location (%) | .180 | ||
| Upper 1/3 | 8 (17.8) | 14 (24.6) | |
| Middle 1/3 | 6 (13.3) | 7 (12.3) | |
| Lower 1/3 | 30 (66.7) | 29 (50.9) | |
| More than 1/3 | 1 (2.2) | 7 (12.3) | |
| Histopathology (%) | .151 | ||
| Papillary | 10 (22.2) | 4 (7.0) | |
| Tubular | 26 (57.8) | 37 (64.9) | |
| Mucinous | 3 (6.7) | 4 (7.0) | |
| Signet-ring cell | 6 (13.3) | 12 (21.1) | .766 |
| Primary tumor size, cm | |||
| ≤5 | 40 (87.0) | 61 (89.7) | |
| >5 | 6 (13.0) | 7 (10.3) | |
| Tumor differentiation (%) | .307 | ||
| Well moderately differentiated | 20 (44.4) | 19 (33.3) | |
| Poorly differentiated and others | 25 (55.6) | 38 (66.7) | |
| Borrmann type (%) | .263 | ||
| I | 9 (20.0) | 5 (8.8) | |
| II | 16 (35.6) | 17 (29.8) | |
| III | 15 (33.3) | 25 (43.9) | |
| IV | 5 (11.1) | 10 (17.5) | |
| Pathological T stage (%) | <.001 | ||
| T1 | 13 (28.9) | 5 (8.8) | |
| T2 | 9 (20.0) | 4 (7.0) | |
| T3 | 13 (28.9) | 12 (21.1) | |
| T4 | 10 (22.2) | 35 (63.2) | |
| Pathological N stage (%) | .001 | ||
| N0 | 23 (51.1) | 13 (22.8) | |
| N1 | 11 (24.4) | 7 (12.3) | |
| N2 | 4 (8.9) | 17 (29.8) | |
| N3 | 7 (15.6) | 20 (35.1) | |
| Metastatic lymph nodes | 3.9 ± 6.0 | 9.3 ± 7.5 | <.001 |
| Pathological M stage (%) | .001 | ||
| M0 | 44 (97.8) | 42 (73.7) | |
| M1 | 1 (2.2) | 15 (26.3) | |
| TNM stage (%) | <.001 | ||
| I | 18 (40.0) | 6 (10.5) | |
| II | 14 (31.1) | 11 (19.3) | |
| III | 12 (26.7) | 25 (43.9) | |
| IV | 1 (2.2) | 15 (26.3) | |
| Vascular invasion (%) | 5 (11.1) | 7 (12.3) | 1.000 |
| Neural invasion (%) | 5 (11.1) | 8 (14.0) | .770 |